Compare TPVG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | IPHA |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 189.5M |
| IPO Year | 2013 | N/A |
| Metric | TPVG | IPHA |
|---|---|---|
| Price | $4.72 | $1.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $5.90 | $5.75 |
| AVG Volume (30 Days) | ★ 271.6K | 14.5K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | ★ 17.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.67 | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.48 | $1.18 |
| 52 Week High | $7.50 | $2.63 |
| Indicator | TPVG | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 28.71 | 56.03 |
| Support Level | $4.48 | $1.73 |
| Resistance Level | $5.70 | $1.90 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 9.30 | 56.59 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.